PODD

Insulet Corporation

219.86

USD

PODD Earnings Reports

Positive Surprise Ratio

PODD beat 28 of 41 last estimates.

68%

Next Report

Date of Next Report

May 06, 2026

Estimate for Q1 26 (Revenue/ EPS)

$740.63M

$1.22

Implied change from Q4 25 (Revenue/ EPS)

-5.51%

-21.29%

Implied change from Q1 25 (Revenue/ EPS)

+30.16%

+20.79%

Insulet Corporation earnings per share and revenue

On Feb 18, 2026, PODD reported earnings of 1.55 USD per share (EPS) for Q4 25, beating the estimate of 1.48 USD, resulting in a 4.50% surprise. Revenue reached 783.80 million, compared to an expected 784.07 million, with a -0.03% difference. The market reacted with a +4.76% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 24 analysts forecast an EPS of 1.22 USD, with revenue projected to reach 740.63 million USD, implying an decrease of -21.29% EPS, and decrease of -5.51% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

BillionToOne, Inc. Class A Common Stock

Report Date

Mar 04, 2026 For Q4 25

Estimate

$0.08

Actual

$0.11

Surprise

+27.02%

Capricor Therapeutics Inc

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.55

Actual

-$0.62

Surprise

-12.56%

Brainsway Ltd. - ADR

Report Date

Mar 11, 2026 For Q4 25

Estimate

$0.13

Actual

$0.14

Surprise

+6.63%

Sundial Growers Inc. Common Shares

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.01

Actual

$0.04

Surprise

+499.62%

Apyx Medical Corporation Common Stock

Report Date

Mar 10, 2026 For Q4 25

Estimate

-$0.05

Actual

-$0.03

Surprise

+48.63%

MacroGenics, Inc.

Report Date

Mar 09, 2026 For Q4 25

Estimate

-$0.29

Actual

-$0.23

Surprise

+22.40%

Biote Corp. Class A Common Stock

Report Date

Mar 11, 2026 For Q4 25

Estimate

$0.05

Actual

$0.06

Surprise

+17.65%

Exagen Inc. Common Stock

Report Date

Mar 10, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.20

Surprise

-4.22%

Nephros Inc.

Report Date

Mar 12, 2026 For Q4 25

Estimate

$0.01

Actual

$0.01

Surprise

-1.96%

Myomo Inc.

Report Date

Mar 09, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.08

Surprise

+2.19%

FAQ

What were Insulet Corporation's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Insulet Corporation reported EPS of $1.55, beating estimates by 4.5%, and revenue of $783.80M, -0.03% below expectations.

How did the market react to Insulet Corporation's Q4 2025 earnings?

The stock price moved up 4.76%, changed from $246.34 before the earnings release to $258.07 the day after.

When is Insulet Corporation expected to report next?

The next earning report is scheduled for May 06, 2026.

What are the forecasts for Insulet Corporation's next earnings report?

Based on 24 analysts, Insulet Corporation is expected to report EPS of $1.22 and revenue of $740.63M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.